NanoViricides, Inc. (NNVC)

USD 1.5

(0.67%)

Total Debt Summary of NanoViricides, Inc.

  • NanoViricides, Inc.'s latest annual total debt in 2024 was - USD , down 0.0% from previous year.
  • NanoViricides, Inc.'s latest quarterly total debt in 2024 Q4 was - USD , down 0.0% from previous quarter.
  • NanoViricides, Inc. reported annual total debt of - USD in 2023, down -100.0% from previous year.
  • NanoViricides, Inc. reported annual total debt of 94.78 Thousand USD in 2022, down -0.54% from previous year.
  • NanoViricides, Inc. reported quarterly total debt of - USD for 2024 Q4, down 0.0% from previous quarter.
  • NanoViricides, Inc. reported quarterly total debt of - USD for 2024 Q3, down 0.0% from previous quarter.

Annual Total Debt Chart of NanoViricides, Inc. (2024 - 2005)

Historical Annual Total Debt of NanoViricides, Inc. (2024 - 2005)

Year Total Debt Total Debt Growth
2024 - USD 0.0%
2023 - USD -100.0%
2022 94.78 Thousand USD -0.54%
2021 95.3 Thousand USD -91.68%
2020 1.14 Million USD 0.0%
2019 - USD 0.0%
2018 - USD -100.0%
2017 3.95 Million USD -54.04%
2016 8.6 Million USD 19.87%
2015 7.18 Million USD -20.54%
2014 9.03 Million USD 160.59%
2013 3.46 Million USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%
2010 - USD 0.0%
2009 - USD 0.0%
2008 - USD 0.0%
2007 - USD -100.0%
2006 917.08 Thousand USD 0.0%
2005 - USD 0.0%

Peer Total Debt Comparison of NanoViricides, Inc.

Name Total Debt Total Debt Difference
AIM ImmunoTech Inc. 495 Thousand USD 100.0%
Ampio Pharmaceuticals, Inc. 274 Thousand USD 100.0%
Armata Pharmaceuticals, Inc. 120.37 Million USD 100.0%
Actinium Pharmaceuticals, Inc. 2.11 Million USD 100.0%
Azitra, Inc. 885.94 Thousand USD 100.0%
Can-Fite BioPharma Ltd. 39.99 Thousand USD 100.0%
Chromocell Therapeutics Corporation 1.26 Million USD 100.0%
Calidi Biotherapeutics, Inc. 7.23 Million USD 100.0%
CEL-SCI Corporation 13.57 Million USD 100.0%
iBio, Inc. 4.46 Million USD 100.0%
Lineage Cell Therapeutics, Inc. 2.95 Million USD 100.0%
MAIA Biotechnology, Inc. - USD NaN%
Matinas BioPharma Holdings, Inc. 3.55 Million USD 100.0%
Navidea Biopharmaceuticals, Inc. 2.43 Million USD 100.0%
NovaBay Pharmaceuticals, Inc. 2.74 Million USD 100.0%
Oragenics, Inc. 312.7 Thousand USD 100.0%
BiomX Inc. 15.09 Million USD 100.0%
BiomX Inc. 15.09 Million USD 100.0%
Protalix BioTherapeutics, Inc. 26.28 Million USD 100.0%
Palatin Technologies, Inc. 590.33 Thousand USD 100.0%
Scorpius Holdings, Inc. 14.04 Million USD 100.0%